Rapiblyk

Rapiblyk is an IV beta-blocker used in hospitals to quickly control heart rate during acute supraventricular tachycardia (like atrial fibrillation or flutter). Its ultra-rapid action slows the heart without significantly lowering blood pressure.

Molecule Details :

  • Molecule Name :

    Landiolol
  • Innovator :

    AOP ORPHAN PHARMACEUTICALS AG
  • Approval Date :

    22-Nov-24
  • NCE-1 Date :

    22-Nov-28
  • NCE Date :

    22-Nov-29
  • Dosage Form :

    Intravenous Powder Injection
  • Strength :

    280MG BASE-VIAL
  • Therapeutic Category :

    Cardiovascular Agents
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?